Estimación de los costes sanitarios relacionados con las fracturas osteoporóticas en pacientes posmenopáusicas en España-Reference-Cited by-同舟云学术

Estimación de los costes sanitarios relacionados con las fracturas osteoporóticas en pacientes posmenopáusicas en España

Published:2014-04-17 Issue:1 Volume:12 Page:1-9
ISSN:1695-405X
Container-title:PharmacoEconomics Spanish Research Articles
language:es
Short-container-title:PharmacoEcon Span Res Artic

Author:

González Yolanda,Sicras Antoni,Larraínzar Ricardo,Sorio Francesc,Canals Laura,Lizán Luis,Calvo Emilio

Publisher

Springer Science and Business Media LLC

Subject

Health Policy,Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Link

http://link.springer.com/content/pdf/10.1007/s40277-014-0029-8.pdf

Reference50 articles.

1. Rosen CJ. Clinical practice. Postmenopausal osteoporosis. N Engl J Med. 2005;353:595–603.

2. WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 843. Disponible en: http://whqlibdoc.who.int/trs/WHO_TRS_843.pdf . Accedido el 28 de Febrero de 2013.

3. Lim LS, Hoeksema LJ, Sherin K. Screening for osteoporosis in the adult US population ACPM position statement on preventive practice. Am J Prev Med. 2009;36:366–75.

4. Álvarez J. Prevención de la osteoporosis: el coste de la desinformación del paciente. Rev Esp Econ Salud. 2002;1:24–6.

5. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17:1726.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Delphi consensus on the management of Spanish patients with osteoporosis at high risk of fracture: OSARIDELPHI study;Archives of Osteoporosis;2023-08-23

2. Coste de los efectos adversos asociados a enzalutamida o apalutamida en el tratamiento del cáncer de próstata hormonosensible metastásico en España;Economía de la Salud;2022-07

3. Impacto presupuestario de enzalutamida en el tratamiento del cáncer de próstata hormonosensible metastásico en España;Economía de la Salud;2021-12

4. Long-term clinical and socio-economic outcomes following wrist fracture: a systematic review and meta-analysis;Osteoporosis International;2021-11-11

5. Cost of fremanezumab, erenumab, galcanezumab and onabotulinumtoxinA associated adverse events, for migraine prophylaxis in Spain;Expert Review of Pharmacoeconomics & Outcomes Research;2020-06-02